CN106955351A - 一种抗老年痴呆的药物组合物 - Google Patents

一种抗老年痴呆的药物组合物 Download PDF

Info

Publication number
CN106955351A
CN106955351A CN201610009914.3A CN201610009914A CN106955351A CN 106955351 A CN106955351 A CN 106955351A CN 201610009914 A CN201610009914 A CN 201610009914A CN 106955351 A CN106955351 A CN 106955351A
Authority
CN
China
Prior art keywords
pharmaceutical composition
senile dementia
effect
hexaazacyclotritriacontane
oleracein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610009914.3A
Other languages
English (en)
Inventor
周艳玲
鹿宁
邹蓉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610009914.3A priority Critical patent/CN106955351A/zh
Publication of CN106955351A publication Critical patent/CN106955351A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及抗老年痴呆的药物组合物，该药物组合物由以下成份组成：诺卡胺100-500mg；咖啡因20-30mg；延胡索乙素2-16mg；马齿苋酰胺E 2-10mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯10-20mg；人尿激肽原酶1-3mg。该药物组合物抗老年痴呆效果好，副作用小。

Description

一种抗老年痴呆的药物组合物
技术领域
本发明属于生物医药技术领域，涉及一种药物组合物，具体涉及一种抗老年痴呆的药物组合物。
背景技术
老年痴呆症，是一种中枢神经系统的退行性疾病。其临床表现为认知和记忆能力的不断恶化，日常生活能力进行性减退以及出现各种精神分裂症状和行为障碍。老年痴呆症已经严重的威胁到老年人的生命，给家庭和社会带来了沉重的负担。因而，研究和开发出一种可以抗老年痴呆症的药物具有十分重要的社会意义和临床意义。
目前，抗老年痴呆症药物的研发引起世界各国医药界的高度重视，随着科学家们对老年神经生理、生化、药理方面的深入研究，相关抗老年痴呆症的药物开发研究也取得了较大的进步。
目前临床治疗老年痴呆症的药物包括：1.作用于胆碱能系统的药物：(1)胆碱酯酶抑制剂为最常用药物，如多奈哌齐等，适用于中轻度老年痴呆症，可改善症状，但不能根治疾病；(2)胆碱能受体激动剂，如占诺美林；2.脑代谢改善药物：(1)脑细胞激活剂：吡咯烷酮类药物如吡拉西坦、奥拉西坦、茴拉西坦、奈非西坦等，具有激活、保护、修复大脑神经细胞的作用，能够抵抗物理、化学因素所致的脑功能损害，改善由缺氧所造成的逆行性遗忘，对轻中度老年痴呆症有效；(2)脑循环改善剂：扩张血管，增加动脉和末梢组织血流量，从而改善脑微循环，对痴呆患者的抑郁情绪和注意障碍有改善作用。3.钙离子拮抗剂：如尼莫地平；4.神经细胞营养药：如脑活素；5.非甾体抗炎药：如布洛芬；6.神经营养因子；7.自由基清除剂和抗氧化剂：常用的药物有维生素E、银杏叶提取物和褪黑激素等。
虽然上述药物在临床应用上已经显示出一定的疗效，但在长期使用过程中存在严重的不可避免的副作用，而且治疗效果不显著。因此，寻找一种治疗老年痴呆症效果显著、副作用小的药物是目前亟需解决的难题。
发明内容
本发明的目的在于克服现有技术中存在的缺点，提供一种抗老年痴呆的药物组合物，该药物组合物抗老年痴呆效果好，副作用小。
为了实现上述目的，本发明提供如下技术方案：一种抗老年痴呆的药物组合物，其特征是，该药物组合物由以下成份组成：诺卡胺100-500mg；咖啡因20-30mg；延胡索乙素2-16mg，马齿苋酰胺E2-10mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯10-20mg；人尿激肽原酶1-3mg。
进一步地，其中，该药物组合物由以下成份组成：诺卡胺300mg；咖啡因25mg；延胡索乙素10mg；马齿苋酰胺E 8mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯15mg；人尿激肽原酶2mg。
与现有的药物相比，本发明的抗老年痴呆的药物组合物具有如下有益技术效果：
1、其通过各种药物成份的组合，具有显著的抗老年痴呆的作用，效果非常明显。
2、其通过严格限定各种药物成份的含量，使得该药物组合物具有很小的副作用，对人体的其它器官的损伤较小。
具体实施方式
下面结合实施例对本发明进一步说明，实施例的内容不作为对本发明的保护范围的限制。
实施例1
该实施例的抗老年痴呆的药物组合物由以下成份组成：诺卡胺100mg；咖啡因20mg；延胡索乙素2mg；马齿苋酰胺E 2mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯10mg；人尿激肽原酶1mg。
通过临床试验发现，该药物组合物抗中、轻度老年痴呆效果好，且几乎没有副作用，可以长期服用。
实施例2
该实施例的抗老年痴呆的药物组合物由以下成份组成：诺卡胺500mg；咖啡因30mg；延胡索乙素16mg；马齿苋酰胺E 10mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯20mg；人尿激肽原酶3mg。
通过临床试验发现，该药物组合物抗重度老年痴呆效果好，但是具有一定的副作用，不过与现有的抗老年痴呆药物对比发现，副作用比现有的抗老年痴呆药物的副作用要小的多。
实施例3
该实施例的抗老年痴呆的药物组合物由以下成份组成：诺卡胺300mg；咖啡因25mg；延胡索乙素10mg；马齿苋酰胺E 8mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯15mg；人尿激肽原酶2mg。
通过临床试验发现，该药物组合物抗中、轻、重度老年痴呆效果都很好，且副作用比较小，是最理想的一种抗老年痴呆药物。
本发明的上述实施例仅仅是为清楚地说明本发明所作的举例，而并非是对本发明的实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无法对所有的实施方式予以穷举。凡是属于本发明的技术方案所引伸出的显而易见的变化或变动仍处于本发明的保护范围之列。

Claims (2)

1.一种抗老年痴呆的药物组合物，其特征是，该药物组合物由以下成份组成：诺卡胺100-500mg；咖啡因20-30mg；延胡索乙素2-16mg；马齿苋酰胺E 2-10mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯10-20mg；人尿激肽原酶1-3mg。
2.根据权利要求1所述的抗老年痴呆的药物组合物，其特征是，该药物组合物由以下成份组成：诺卡胺300mg；咖啡因25mg；延胡索乙素10mg；马齿苋酰胺E 8mg；2-[(2-O-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯15mg；人尿激肽原酶2mg。
CN201610009914.3A 2016-01-08 2016-01-08 一种抗老年痴呆的药物组合物 Pending CN106955351A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610009914.3A CN106955351A (zh) 2016-01-08 2016-01-08 一种抗老年痴呆的药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610009914.3A CN106955351A (zh) 2016-01-08 2016-01-08 一种抗老年痴呆的药物组合物

Publications (1)

Publication Number Publication Date
CN106955351A true CN106955351A (zh) 2017-07-18

Family

ID=59480652

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610009914.3A Pending CN106955351A (zh) 2016-01-08 2016-01-08 一种抗老年痴呆的药物组合物

Country Status (1)

Country Link
CN (1) CN106955351A (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292607A1 (en) * 2005-11-23 2008-11-27 Elizabeth Mazzio Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
CN102648914A (zh) * 2011-02-24 2012-08-29 杭州赛利药物研究所有限公司 咖啡因在制备治疗老年痴呆症药物中的用途
CN102657644A (zh) * 2012-04-01 2012-09-12 江西农业大学 诺卡胺在制备抗老年痴呆药物中的应用
CN103251635A (zh) * 2013-05-06 2013-08-21 暨南大学 2-[(2-o-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯的用途
CN103565805A (zh) * 2012-07-31 2014-02-12 北京以岭药业有限公司 延胡索乙素在制备治疗老年痴呆的药物中的应用
CN103948596A (zh) * 2014-05-04 2014-07-30 山东大学 马齿苋酰胺e在制备抗老年痴呆神经退行性疾病药物中的应用
CN104940914A (zh) * 2015-07-10 2015-09-30 广东天普生化医药股份有限公司 人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292607A1 (en) * 2005-11-23 2008-11-27 Elizabeth Mazzio Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
CN102648914A (zh) * 2011-02-24 2012-08-29 杭州赛利药物研究所有限公司 咖啡因在制备治疗老年痴呆症药物中的用途
CN102657644A (zh) * 2012-04-01 2012-09-12 江西农业大学 诺卡胺在制备抗老年痴呆药物中的应用
CN103565805A (zh) * 2012-07-31 2014-02-12 北京以岭药业有限公司 延胡索乙素在制备治疗老年痴呆的药物中的应用
CN103251635A (zh) * 2013-05-06 2013-08-21 暨南大学 2-[(2-o-葡萄糖基-5-羟基苯甲酰基)胺基]-5-羟基苯甲酸甲酯的用途
CN103948596A (zh) * 2014-05-04 2014-07-30 山东大学 马齿苋酰胺e在制备抗老年痴呆神经退行性疾病药物中的应用
CN104940914A (zh) * 2015-07-10 2015-09-30 广东天普生化医药股份有限公司 人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
梁月荣等: "《茶资源综合利用》", 30 November 2013, 浙江大学出版社 *

Similar Documents

Publication Publication Date Title
Maas et al. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia
Yamashita et al. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons
US10188688B2 (en) Therapy for promoting cell growth
Kalaria Similarities between Alzheimer's disease and vascular dementia
Liu et al. Recent advances and perspectives of postoperative neurological disorders in the elderly surgical patients
Tota et al. Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic neurotransmission, and brain derived neurotrophic factor in rats
Maiese Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease
Hamel et al. Neurovascular and cognitive failure in Alzheimer’s disease: benefits of cardiovascular therapy
Rong et al. Enhancing therapeutic efficacy of donepezil by combined therapy: a comprehensive review
Shi et al. Pirfenidone inhibits epidural scar fibroblast proliferation and differentiation by regulating TGF-β1-induced Smad-dependent and-independent pathways
Chen et al. Melatonin attenuates scopolamine-induced cognitive impairment via protecting against demyelination through BDNF-TrkB signaling in the mouse dentate gyrus
Miao et al. Ginsenoside Rb1 attenuates isoflurane/surgery-induced cognitive dysfunction via inhibiting neuroinflammation and oxidative stress
Li et al. Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway
Proske et al. Transverse versus midline incision for upper abdominal surgery
CN106955351A (zh) 一种抗老年痴呆的药物组合物
Zhang et al. Shenmayizhi formula combined with ginkgo extract tablets for the treatment of vascular dementia: a randomized, double‐blind, controlled trial
Fan et al. Delayed metformin treatment improves functional recovery following traumatic brain injury via central AMPK-dependent brain tissue repair
Ferreira et al. Fish oil provides a sustained antiamnesic effect after acute, transient forebrain ischemia but not after chronic cerebral hypoperfusion in middle-aged rats
Uslu et al. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism
CA3148145A1 (en) Food supplement, for use as adjuvant, for preventing vascular dementia.
Plaschke et al. Surgery‐induced changes in rat IL‐1β and acetylcholine metabolism: role of physostigmine
Kalivas et al. Catatonia after liver and kidney transplantation
Maratha et al. Alzheimer’s disease: Neurotransmitters involved and the possible new strategies
RU2750418C1 (ru) Средство, обладающее противогипоксической, антиамнестической и нейропротекторной активностью
Vanakoski et al. Effects of ceronapril alone or in combination with alcohol on psychomotor performance in healthy volunteers: a placebo-controlled, crossover study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
DD01 Delivery of document by public notice
DD01 Delivery of document by public notice

Addressee: Zhou Yanling

Document name: Deemed as a notice of withdrawal

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170718